Low levels of key protein may indicate pancreatic cancer risk

A protein that dwindles in response to obesity and a sedentary lifestyle may one day help doctors predict which people are at increased risk for pancreatic cancer, new research by Dana-Farber Cancer Institute and collaborating scientists indicates.

In a report in the Aug. 15 issue of Cancer Research, the investigators found that, in a large study group, people with the lowest blood levels of a protein called IGFBP-1 were twice as likely to develop pancreatic cancer as those with higher levels. Though much work remains to determine if the protein -- whose acronym stands for insulin-like growth factor binding protein-1 -- is a reliable indicator of pancreatic cancer risk, the finding adds to the scientific understanding of how the disease develops.

"The levels of insulin and another circulating hormone, insulin-like growth factor or IGF, are modified by obesity and sedentary lifestyle, and there is evidence that these hormones may stimulate the growth of pancreatic cancer cells," said the study's lead author, Brian Wolpin, MD, of Dana-Farber. "When IGF binds to proteins like IGFBP-1, there may be less IGF available to bind to pancreatic cancer cells and promote their growth. We wanted to determine whether IGFBP-1 levels in the blood were associated with pancreatic cancer risk."

The investigators measured circulating IGFBP-1 levels in a select group of participants in four large, ongoing health studies: the Health Professionals Follow-up Study, the Nurses' Health Study, the Physicians' Health Study, and the Women's Health Initiative. They collected blood samples from 573 participants and, four or more years later, checked IGFBP-1 levels in the samples of 144 people who developed pancreatic cancer and 429 who did not.

They found that the quarter of the group whose IGFBP-1 levels were lowest had twice the risk of developing pancreatic cancer of those in the top three quarters. The connection became even stronger over time: Among cases diagnosed at least eight years after blood collection, those in the bottom quarter of IGFBP-1 levels had nearly three-and-a-half times the pancreatic cancer risk of those in the upper quarters.

The risk may be elevated because higher amounts of IGFBP-1 are able to "soak up" more IGF, leaving less available to spur pancreatic cancer cell growth, or because IGFBP-1 has some cancer-blocking properties of its own, said Wolpin, who is also an instructor in medicine at Harvard Medical School. Another possibility is that other molecules may be involved, for which IGFBP-1 acts as an intermediary.

"It's known that a variety of proteins are affected by obesity and sedentary lifestyle," he added. "Studies are exploring whether a subset of these may play a role in the risk of developing pancreatic cancer. More research is also needed on how alterations in insulin and proteins in the IGF family alter the risk of this difficult disease."

Source: Dana-Farber Cancer Institute

Related stories:

Certain anticancer agents could be harmful to patients with heart disease
A set of promising new anticancer agents could have unforeseen risks in individuals with heart disease, suggests research at Washington University School of Medicine in St. Louis. The anticancer drugs — which go by the strange name of hedgehog antagonists — interfere with a biochemical process that promotes growth in some cancer cells. But the researchers showed that interfering with this biochemical process in mice with heart disease led to further deterioration of cardiac function and ultimately death.
Potential biomarkers for pancreatic cancer identified
In a new study in PLoS Medicine, Samir Hanash and colleagues from Fred Hutchinson Cancer Research Center in Seattle report the identification of proteins that appear in increased numbers at an early stage of pancreatic tumor development in a mouse model and may be a useful tool in detecting early tumors in humans.
Synthetic molecules hold promise for new family of anti-cancer drugs
Synthetic molecules designed by two Hebrew University of Jerusalem researchers have succeeded in reducing and even eliminating the growth of human malignant tissues in mice, while having no toxic effects on normal tissue.
New treatment combination safe for pancreatic cancer patients
Treating pancreatic cancer with a combination of chemotherapy, biotherapy and radiotherapy prior to surgery is safe and may be beneficial for patients, according to a University of Pittsburgh Cancer Institute (UPCI) study presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
OHSU discovery may lead to early cancer detection
This week researchers in the Oregon Health & Science University (OHSU) Oregon Stem Cell Center and the OHSU Digestive Health Center are shining a new ray of hope on patients with pancreatic cancer. They’ve developed new reagents, or antibodies, that can recognize this often lethal disease. This important discovery may one day lead to earlier detection and treatment.
Traditional herbal medicine kills pancreatic cancer cells, researchers report
An herb used in traditional medicine by many Middle Eastern countries may help in the fight against pancreatic cancer, one of the most difficult cancers to treat. Researchers at the Kimmel Cancer at Jefferson in Philadelphia have found that thymoquinone, an extract of nigella sativa seed oil, blocked pancreatic cancer cell growth and killed the cells by enhancing the process of programmed cell death.
Heart failure patients may suffer similarly to advanced cancer patients
Heart failure outpatients have similar numbers of symptoms and levels of depression and spiritual well-being as patients with advanced lung and pancreatic cancer, researchers reported at the American Heart Association’s 9th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke.
Minimally invasive pancreas surgery leads to fewer complications, study finds
When surgeons need to remove part of the pancreas, performing the operation with minimally invasive techniques offers patients a shorter hospital stay and fewer complications, researchers have concluded.

News discussion:

Medicine & Health news